financetom
Business
financetom
/
Business
/
Cloud industry group calls for EU interim measure against Broadcom over VMware
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cloud industry group calls for EU interim measure against Broadcom over VMware
Mar 19, 2026 8:34 AM

BRUSSELS, March 19 (Reuters) - Lobbying group Cloud

Infrastructure Services Providers in Europe on Thursday urged EU

antitrust regulators to temporarily stop Broadcom ( AVGO ) from

ending its VMware Cloud Service Provider programme in Europe,

ramping up its fight against the U.S. tech company.

CISPE, which has nearly 50 members across Europe and counts

Microsoft ( MSFT ) and Amazon ( AMZN ) as associate members,

sued the European Commission last year for approving Broadcom's ( AVGO )

acquisition of VMware in 2023, saying the EU competition

watchdog had failed to examine the deal properly.

It took its latest grievance about Broadcom ( AVGO ) to the

Commission after the company revamped its VMware cloud service

provider ecosystem late last year and asked for an interim

measure.

"In January 2026 Broadcom ( AVGO ) signalled the termination of its

VMware Cloud Service Provider program in Europe. This unilateral

decision removed all but a tiny minority of hand selected

partners and excluded most European CSPs from selling VMware

products," CISPE said in a statement.

"Both cloud providers and their customers - are being

irreparably damaged by Broadcom's ( AVGO ) unfair actions," CISPE

Secretary General Francisco Mingorance said.

The Commission and Broadcom ( AVGO ) did not immediately respond to

emailed requests for comment.

CISPE said an EU interim measure should immediately suspend

Broadcom's ( AVGO ) termination of its VCSP partner programme, allow them

to be readmitted to the programme and include protection

measures against retaliation from Broadcom ( AVGO ).

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved